|
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
|
27 November 2014 |
|
AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
|
13 November 2014 |
|
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
|
29 October 2014 |
|
AstraZeneca strengthens partnership with the University of Cambridge
|
27 October 2014 |
|
Positive results from Phase IIb benralizumab study in severe asthma
|
10 October 2014 |
|
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
|
25 September 2014 |
|
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease
|
16 September 2014 |
|
AstraZeneca and Redx Pharma agree research collaboration
|
03 September 2014 |
|
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
|
02 September 2014 |
|
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
|
19 August 2014 |